Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Morales
Leilani
L
Paridaens
Robert
R
Timmerman
Dirk
D
Neven
Patrick
P
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000187:drug effects*; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use*; D014463:Ultrasonography; D014591:Uterine Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000000981:diagnostic imaging
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen